文献速递类风湿关节炎

类风湿关节炎患者与医生整体评估的差异:核心结局指标表现的元流行病学研究

Understanding patient and physician global assessments in rheumatoid arthritis: A meta-epidemiological study of core outcome set performance.
PubMed 文献 · Semin Arthritis Rheum · 2026-06-14

该研究系统综述73项双盲随机对照试验(165个随机比较,33,956例类风湿关节炎患者),比较靶向治疗中医生与患者整体评估的改善差异。医生评估的标准化均数差(SMD)为-0.60,患者评估为-0.50,差异ΔSMD为-0.09,主要由肿胀关节计数驱动,疼痛仅与患者评估独立相关。

要点

  • 靶向治疗中医生整体评估改善略大于患者整体评估,ΔSMD为-0.09。
  • 肿胀关节计数是医生与患者评估差异的唯一显著关联域。
  • 疼痛仅独立关联患者整体评估,提示需更好整合患者报告结局。

核心结论

  • 靶向治疗在医生评估的结局上显示比患者报告结局更大的改善,这一差异主要由肿胀关节计数驱动。
  • 疼痛仍是患者评估的独立决定因素,强调需在类风湿关节炎试验设计中更好地整合患者报告结局。

研究设计与样本

  • 系统综述与元流行病学分析,纳入比较靶向治疗与安慰剂的随机对照试验。
  • 共纳入73项双盲随机对照试验,包含165个随机比较,涉及33,956例类风湿关节炎患者。
  • 计算8个RA-COS域的标准化均数差(SMD),以ΔSMD Global(医生整体评估SMD减患者整体评估SMD)评估一致性,并行多变量元分析和元回归。

主要发现

  • 医生整体评估的SMD为-0.60(95% CI -0.65至-0.55),患者整体评估的SMD为-0.50(95% CI -0.54至-0.46)。
  • ΔSMD Global为-0.09(95% CI -0.12至-0.05)。
  • 单变量元回归显示残疾、压痛关节计数和肿胀关节计数与两种评估关联最强,但仅肿胀关节计数与ΔSMD Global显著相关。
  • 疼痛仅独立关联患者整体评估。

关键数值与推荐

  • RA-COS域包括医生整体评估、患者整体评估、残疾、压痛关节计数、肿胀关节计数、疼痛、急性期反应物和疲劳。
  • 主要一致性指标为ΔSMD Global(医生整体评估SMD减患者整体评估SMD)。

临床怎么用

  • 临床解读类风湿关节炎试验结果时需注意医生与患者整体评估的差异,尤其肿胀关节计数对差异的驱动作用。
  • 在试验设计和临床决策中应更重视患者报告结局,特别是疼痛对患者整体评估的独立影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess agreement between physician and patient global assessment improvements in randomised controlled trials (RCT) of targeted therapies for rheumatoid arthritis and to identify which core outcome domains best explain changes in each assessment and their discrepancies. METHODS: We conducted a systematic review and meta-epidemiological analysis of RCTs comparing targeted therapies with placebo. Standardised mean differences (SMDs) were calculated for all eight RA-COS domains: Physician global assessment, Patient global assessment, Disability, Tender joint count (TJC), Swollen joint count (SJC), Pain, Acute phase reactants, and Fatigue. Agreement between physician and patient assessments was assessed as ΔSMD Global (i.e., SMD Physician global assessment - SMD Patient global assessment). Multivariate meta-analyses were performed to calculate SMD for the remaining domains. Multiple imputation followed by meta-regression analyses identified domain-level predictors of global assessment changes. RESULTS: We identified 73 double-blind RCTs (165 randomised comparisons) involving 33,956 RA patients. Physician assessments demonstrated slightly greater treatment effects (SMD -0.60; 95% CI -0.65 to -0.55) compared with patient assessments (SMD -0.50; 95% CI -0.54 to -0.46): ΔSMDGlobal = -0.09 (95% CI -0.12 to -0.05). Univariable meta-regression identified disability, TJC and SJC as the strongest associations of both assessments, yet SJC was the only domain significantly associated with the contrast between these (ΔSMDGlobal). Pain was independently associated only with patient global assessment. CONCLUSION: Targeted therapies show larger improvements in physician-assessed outcomes than on patient-reported outcomes, largely driven by SJC. Pain remains a distinct determinant of patient assessments, underscoring the need to better integrate patient-reported outcomes into RA trial design. REGISTRATION: The protocol was registered on PROSPERO (2025-02-14). REGISTRATION NUMBER: CRD420250652342.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lage-Hansen PR, Haugegaard T, Sofíudóttir BK, et al. Understanding patient and physician global assessments in rheumatoid arthritis: A meta-epidemiological study of core outcome set performance. Semin Arthritis Rheum. 2026. PMID: 42330661. doi:10.1016/j.semarthrit.2026.153023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。